Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin

Behavioural Brain Research

Volumn 259, Issue , 2014, Pages 70-77

  Santiago, Ronise M ^a   Barbiero, Janaína ^a   Gradowski, Raisa W ^a   Bochen, Suelen ^a   Lima, Marcelo M S ^a   Da Cunha, Cláudio ^a   Andreatini, Roberto ^a   Vital, Maria A B F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

6 OHDA; Depressive like behavior; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; OXIDOPAMINE; SEROTONIN; SUCROSE;

ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLIMBING; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; EMOTIONAL DISORDER; FORCED SWIMMING TEST; HIPPOCAMPUS; HISTOPATHOLOGY; HOPELESSNESS; IMMOBILITY; MALE; NEUROTRANSMISSION; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; RAT; SWIMMING; TISSUE DISTRIBUTION;

6-OHDA; DEPRESSIVE-LIKE BEHAVIOR; PARKINSON'S DISEASE;

ADRENERGIC AGENTS; ANIMALS; CORPUS STRIATUM; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE; EXPLORATORY BEHAVIOR; FOOD PREFERENCES; HIPPOCAMPUS; MALE; NEURONS; OXIDOPAMINE; RATS; RATS, WISTAR; SEROTONIN; SUBSTANTIA NIGRA; SUCROSE; SWEETENING AGENTS; SWIMMING; TIME FACTORS;

EID: 84887579338     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.10.035     Document Type: Article

References (39)

1. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
2. Elbaz A., Tranchant C. Epidemiologic studies of environmental exposures in Parkinson's disease. J Neurol Sci 2007, 262:37-44.
3. Lima M.M.S., Martins E.F., Delattre A.M., Proença M.B., Mori M.A., Carabelli B., et al. Motor and non-motor features of Parkinson's disease: a review of clinical and experimental studies. CNS Neurol Disord Drug Targets 2012, 11:439-449.
4. Den Oudsten B.L., Van Heck G.L., De Vries J. Quality of life and related concepts in Parkinson's disease: a systematic review. Mov Disord 2007, 22:1528-1537.
5. Hemmerle A.M., Herman J.P., Seroog K.B. Stress, depression and Parkinson's disease. Exp Neurol 2012, 233:79-86.
6. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
7. Soh S.E., Morris M.E., McGinley J.L. Determinants of health-related quality of life in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2011, 17:1-9.
8. Barnum C.J., Tansey M.G. Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease. Curr Neurol Neurosci Rep 2012, 12:350-358.
9. Frisina P.G., Haroutunian V., Libow L.S. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:144-148.
10. Wolters E.C. Variability in the clinical expression of Parkinson's disease. J Neurol Sci 2008, 266:197-203.
11. Althaus A., Becker O.A., Spottke A., Dengler R., Schneider F., Kloss M., et al. Frequency and treatment of depressive symptoms in a Parkinson's disease registry. Parkinsonism Relat Disord 2008, 14:626-632.
12. Schrag A. Psychiatric aspects of Parkinson's disease: an update. J Neurol 2004, 251:795-804.
13. Mayeux R. Depression in the patient with Parkinson's disease. J Clin Psychiatry 1990, 51(Suppl 20-23). discussion 24-25.
14. Dremencov E., Newman M.E., Kinor N., Blatman-Jan G., Schindler C.J., Overstreet D.H., et al. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 2005, 48:34-42.
15. Tan S.K.H., Hartung H., Sharp T., Temel Y. Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus. Neuropharmacology 2011, 61:387-399.
16. Litteljohn D., Mangano E., Shukla N., Hayley S. Interferon-γ deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience 2009, 164:1894-1906.
17. Pankova N.B., Vetrile L.A., Basharova L.A., Krupina N.A., Khlebnikova N.N., Rodina V.I., et al. Immunization of rats with conjugates of dopamine and serotonin with bovine serum albumin prevents the development of experimental MPTP-induced depressive syndrome (electrophysiological parameters). Neurosci Behav Physiol 2004, 34:131-138.
18. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
19. Vuckovic M.G., Wood R.I., Holschneider D.P., Abernathy A., Togasaki D.M., Smith A., et al. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 2008, 32:319-327.
20. Santiago R.M., Barbieiro J., Lima M.M.S., Dombrowski P.A., Andreatini R., Vital M.A.B.F. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1104-1114.
21. Paxinos G., Watson C. The rat brain in stereotaxic coordinates: the new coronal set 2005, Academic Press, San Diego. 5th ed.
22. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
23. Reneric J.P., Bouvard M., Stinus L. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 2002, 136:521-532.
24. Papp M., Willner P., Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl) 1991, 104:255-259.
25. Wang S.H., Zhang Z.J., Guo Y.J., Zhou H., Teng G.J., Chen B.A. Anhedonia and activity deficits in rats: impact of post-stroke depression. J Psychopharmacol 2009, 23:295-304.
26. Slattery D.A., Markou A., Cryan J.F. Evaluation of reward processes in an animal model of depression. Psychopharmacology (Berl) 2007, 190:555-568.
27. Reksidler A.B., Lima M.M.S., Dombrowski P., Andersen M.L., Zanata S.M., Andreatini R., et al. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J Neurosci Methods 2008, 167:268-277.
28. Lima M.M.S., Andersen M.L., Reksidler A.B., Vital M.A.B.F., Tufik S. The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS One 2007, 2:e513.
29. Perry J.C., Hipolide D.C., Tufik S., Martins R.D., Da Cunha C., Andreatini R., et al. Intra-nigral MPTP lesion in rats: behavioral and autoradiography studies. Exp Neurol 2005, 195:322-329.
30. Kanda F., Oishi K., Sekiguchi K., Kuga A., Kobessho H., Shirafuji T., et al. Characteristics of depression in Parkinson's disease: evaluating with Zung's Self-Rating Depression Scale. Parkinsonism Relat Disord 2008, 14:19-23.
31. Malkesman O., Weller A. Two different putative genetic animal models of childhood depression: a review. Prog Neurobiol 2009, 88:153-169.
32. 2C receptors. J Pharmacol Exp Ther 2002, 295:1120-1126.
33. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
34. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997, 8:523-532.
35. Huot P., Fox S.H., Brotchie J.M. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011, 95:163-212.
36. Aarsland D., Pahlhagen S., Ballard C.G., Ehrt U., Svenningsson P. Depression in Parkinson disease: epidemiology, mechanisms and management. Nat Rev Neurol 2012, 8:35-47.
37. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134.
38. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991, 50:743-755.
39. Suzuki K., Miyamoto M., Miyamoto T., Okuma Y., Hattori N., Kamei S., et al. Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease. Parkinsonism Related Disord 2009, 15:15-19.